CClinicalTrials.gg
Status unknownNCT05325749Updated Apr 13, 2022

Whole Exome Screening of Newborns

An observational study in Infant, Newborn, sponsored by Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare. Status unknown at 1 site in Russian Federation. Per ClinicalTrials.gov, last updated 2022-04-13.

Sponsored by Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare · Observational

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
7,000
Sex
All
01

Study summary

The aim of the study is to obtain the initial experience of the inclusive genetic screening of newborn.

Two groups of newborns born in RCOGP will be enlisted to the study:

  1. newborns without developmental features having no variations according to an inherited diseases screening;
  2. newborns showing either phenotypic features or deviations according to MS screening.

The residual volume of the cord blood of all newborns form both groups will be collected and subjected to the whole exome sequencing. The sequencing data will be analyzed in "screening" mode for the first group while for the second group analysis will be performed taking the respective phenotype into account.

The study is planned to cover 7000 newborns in total.

02

Conditions studied

  • Infant, Newborn

Keywords

  • newborn
  • whole exome
  • genetic screening
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All infants born in the RCOGP or under treatment in an ICU departmetn of the RCOGP

Eligibility criteria

Group 1 (newborns without features):

Inclusion Criteria:

  • Infants born in the RCOGP, showing no development features and with no inherited diseases revealed by common screening
  • Informed consent signed by a newborn's representative

Exclusion Criteria:

  • Parents refuse to participate
  • Parent(s) younger 18 years
  • Parent(s) unable to make decisions
  • The infant is older 30 d
  • Blood cannot be collected from the infant

Group 2 (newborns with phenotypic features)

Inclusion Criteria:

  • Infants showing either phenotypic features or deviations according to MS screening
  • Informed consent signed by a newborn's representative

Exclusion Criteria:

  • Parents refuse to participate
  • Parent(s) younger 18 years
  • Parent(s) unable to make decisions
  • Blood cannot be collected from the infant
  • Detailed description of the phenotype is not available
  • The infant's exome has been already sequenced
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
7,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • unaffected

    newborns without developmental features having no variations according to an inherited diseases screening;

    Genetic: Screening · Genetic: Family history record · Other: Questionnaire survey

  • affected

    newborns showing either phenotypic features or deviations according to MS screening

    Genetic: Screening · Genetic: Family history record · Other: Questionnaire survey · Genetic: Diagnostic

  • refused families

    parents refused to enroll their newborns to the study

    Other: Questionnaire survey

  • unaffected born prematurely

    newborns without specific developmental features having no variations according to an inherited diseases screening, born before term

    Genetic: Screening · Genetic: Family history record · Other: Questionnaire survey · Genetic: Selective screening

  • unaffected wirh family history

    newborns without developmental features having no variations according to an inherited diseases screening but with affected relative(s)

    Genetic: Screening · Genetic: Family history record · Other: Questionnaire survey · Genetic: Selective screening

  • unaffected wirh prenatal phenotype

    newborns without developmental features at birth and on, having no variations according to an inherited diseases screening which had been observed to show signs of developmental features during prenatal ultrasound examination

    Genetic: Screening · Genetic: Family history record · Other: Questionnaire survey · Genetic: Selective screening

Interventions

  • GeneticScreening

    Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.

  • GeneticFamily history record

    Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.

  • OtherQuestionnaire survey

    Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.

  • GeneticDiagnostic

    The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline

  • GeneticSelective screening

    The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline

05

What researchers measure

Primary outcomes

  1. Estimate the frequency of revealing patients carrying genotype associated with a monogenic disese.

    The manifestation of pathogenic or likely pathogenic variants leading to a monogenic disease presenting during early age. A genotype is considered having risk of developping a monogenic disease in case pathogenic or probably pathogenic variants are detected corresponding to the inheritance model.

    Time frame: 3-5 months

  2. Phenotype-associated variants

    Pathogenic, likely pathogenic variants or variants of uncertain significance corresponding to the observed clinical conditions

    Time frame: 2 weeks - 2 months

  3. Motivations for refuse to participate

    Questionnaire answers provided by families refused to enroll

    Time frame: 1 day

  4. Acceptance of advanced screening

    Questionnaire answers provided by families accepted screening for variants of low penetrance, no care available etc.

    Time frame: 1 day

Secondary outcomes

  1. Oncological risk

    Pathogenic or a likely pathogenic variant causing high risk of developping a cancer

    Time frame: 1 day

  2. Cardiological risk

    Pathogenic or a likely pathogenic variant causing high risk of developping a cardiomyopathy or a sudden cardiac death

    Time frame: 1 day

  3. Recessive carriers

    Inheritance of a pathogenic or a likely pathogenic variant causing to an autosomal recessive disease

    Time frame: 1 day

06

Study locations

1 of 1 sites recruiting
  • Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
    Moscow, 117997, Russian Federation
    Recruiting
07

Registry details

Key details

Study ID
NCT05325749
Lead sponsor
Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
Responsible party
Sponsor
First posted
Apr 13, 2022
Start date
Jul 10, 2021
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Apr 13, 2022

Study contacts

Jekaterina Shubina, PhD
Contact
jekaterina.shubina@gmail.com
+7 926 721-87-17
Andrey A Bystritskiy, PhD
Contact
andrey.bystritskiy@yandex.ru
+7 903 722-10-34
Dmitriy Y Trofimov, DSc
study director · Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion